Menu
Search
|

Menu

Close
X

Ligand Pharmaceuticals Inc LGND.OQ (NASDAQ Stock Exchange Global Market)

152.00 USD
+3.14 (+2.11%)
As of 11:10 AM EST
chart
Previous Close 148.86
Open 150.30
Volume 24,318
3m Avg Volume 192,526
Today’s High 153.61
Today’s Low 149.10
52 Week High 277.48
52 Week Low 126.77
Shares Outstanding (mil) 21.25
Market Capitalization (mil) 3,154.69
Forward P/E 16.82
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.86 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
192
FY17
141
FY16
109
FY15
72
EPS (USD)
FY18
7.620
FY17
2.042
FY16
-0.136
FY15
9.470
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
16.82
29.37
Price to Sales (TTM)
vs sector
13.02
20.58
Price to Book (MRQ)
vs sector
4.48
4.23
Price to Cash Flow (TTM)
vs sector
13.91
21.21
Total Debt to Equity (MRQ)
vs sector
116.65
13.84
LT Debt to Equity (MRQ)
vs sector
86.18
9.93
Return on Investment (TTM)
vs sector
24.23
13.58
Return on Equity (TTM)
vs sector
38.30
15.11

EXECUTIVE LEADERSHIP

John Kozarich
Non-Executive Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Matthew Foehr
President, Chief Operating Officer, Since 2015
Salary: $442,094.00
Bonus: $265,256.00
John Higgins
Chief Executive Officer, Director, Since 2015
Salary: $611,656.00
Bonus: $550,491.00
Matthew Korenberg
Chief Financial Officer, Executive Vice President - Finance, Since 2018
Salary: $403,438.00
Bonus: $242,063.00
Charles Berkman
Senior Vice President, General Counsel, Secretary, Since 2018
Salary: $362,812.00
Bonus: $174,150.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3911 Sorrento Valley Blvd Ste 11
SAN DIEGO   CA   92121-1402

Phone: +1858.5507500

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

SPONSORED STORIES